Natera, Inc. Q3 2026 Earnings Conference Call - NATERA INC

Explicit Guidance:

• FY2026 Revenue: Raised to $3.005B – $3.035B (midpoint increase of $140M vs prior $2.85B–$2.91B range); explicitly excludes true-ups; assumes steady ASPs and continued volume growth.
• FY2026 Gross Margin: Maintained range of 64% – 66% (midpoint 65%); excludes true-ups from guidance model.
• FY2026 R&D Expense: Top end of range increased by $25M to $1.3B to accommodate accelerated pharma/data demand, MRD clinical trial enrollment, and FIND study costs.
• FY2026 SG&A Expense: Adjusted to include one-time legal spend and additional investments in pharma commercial teams and new Signatera clinical initiatives.
• FY2027 Revenue Outlook: Preliminary planning assumes growth rate similar to current year's unit volume with relatively steady ASPs; expects "another growth year across the board."
• FY2027 Gross Margin: Expected to remain in the 64%–66% range (midpoint) despite potential short-term COGS pressure from new products (Fetal Focus, Signatera Genome), with plans to reduce COGS over 18–24 months.
• FY2027 OPEX: Projected growth of 10%–12% to fund significant investments in Early Cancer Detection (FIND) and MRD clinical trials; commercial team expansion is selective while Women's Health and Organ Health teams remain steady.
• Long-Term Financial Target: Goal to reach $6 billion in revenue by 2029 (doubling from FY2026 base); expects profitability to be achieved "growing into it" alongside the cash flow break-even milestone already met.
• FY2027 ASP Assumption: Conservative planning assumes Signatera ASP of $1,450 (up from ~$1,290 in Q3 2026), though management views $2,000+ as a long-term potential.

Business-Segment Outlook:

• Oncology (Signatera):
  • Volumes: Clinical MRD units grew 56% YoY to 316,000 in Q3; sequential growth of 33,000 units marks a sustained acceleration trend.
  • ASP: Q3 Signatera ASP reached $1,290; long-term path targets $2,000+ driven by guideline adoption and expanded coverage.
  • Product Mix: Growth accelerating across all tumor types; Colorectal and Breast remain largest indications, but rapid expansion in Lung, Bladder, Head & Neck, and Lymphoma.
  • New Tech: "Signatera Genome" with phased/structural variants launched; LOD <1 part per million; selected for multiple global Phase 3 programs (e.g., AFT70).
  • Future Readouts: Sagittarius (CRC) behavioral signal indicates treatment de-escalation in 1/3 patients; Volga (Bladder) data shows 91% 24-month event-free survival for negative patients.
• Pharma & Data Services:
  • Trend: Revenue up ~70% in first three quarters vs full year 2025; strong Q4 expected.
  • Growth Driver: Driven by MRD-guided trials (e.g., Invigor 011), data licensing, and trial design services; expected to meaningfully increase in 2027 and beyond.
  • 2029 Target Contribution: Pharma/data anticipated to contribute several hundred million dollars to the 2029 revenue goal via data abstraction, curation, and scientific support.
• Women's Health:
  • Growth: Mid-to-high single-digit growth driven by "Fetal Focus" launch and integrated deep sequencing; stable ASPs not expected to drive growth, but volumes are strong.
• Organ Health:
  • Growth: Volumes grew nearly 40% YoY in Q3, driven by Medicare coverage for surveillance (effective Aug 30) impacting both ASPs and volumes.
• Early Cancer Detection (ECD):
  • Status: FIND study (30,000 patients) fully enrolled; FDA granted Breakthrough Device Designation in Oct 2026.
  • Timeline: Definitive colorectal cancer readout expected in 2027; commercialization expected post-2028.
  • Impact: Expected to be a "small contributor" to 2028/2029 revenues relative to the total $6B target, serving as an anchor for long-term growth beyond that period.

Market and Competitive Outlook:

• Competitive Landscape: Management welcomes competition (e.g., LabCorp entry into prenatal, other labs entering tumor-informed space), viewing it as validation of the MRD market.
• Differentiation: Relies on deep clinical data generation, technical leadership (Signatera Genome with phased variants), and commercial ease of use; believes the "technical debate is largely settled."
• Adoption Trends: Expecting an "organic flywheel" where oncologists adopt MRD in one cancer type and expand to others; data indicates ctDNA is shifting from prognostic to predictive of treatment decisions (e.g., de-escalation in CRC).
• Global Expansion: Japan launch of CRC and Muscle-Invasive Bladder Cancer indications expected to be as fast or faster than U.S. adoption due to high incidence rates and existing clinician familiarity.

Macro / Industry Outlook:

• Reimbursement (Moldy-X): Medicare coverage for HCC (early-stage hepatocellular carcinoma) granted; expects 9–10 additional submissions to be resolved in the coming months, significantly expanding the Total Addressable Market (TAM).
• Regulatory Environment: FDA Breakthrough Designation for ECD assay; expects FDA to potentially adopt Signatera MRD status as a primary or surrogate endpoint in drug trials in the future.
• Economic/Medical Trends: Shift toward bladder-sparing approaches and de-escalation of therapy based on molecular response; demand for real-world evidence in drug development.

Strategic Initiatives:

• Leadership Transition: Steve Chapman stepping down as CEO (effective immediately); Solomon Moscovich appointed as 3rd CEO; Chapman remains as consultant/board advisor.
• Technology Upgrades: Full integration of "Signatera Genome" with phased/structural variants to enhance sensitivity; investing in new clinical trials (Signal ER-101, AFT70 Navigate) to drive breast cancer guideline inclusion.
• Capacity & Operations: Accelerated investments in pharma-specific offerings, commercial teams, and lab capacity to handle surging demand; OPEX ramp-up to support this expansion.
• Geographic Expansion: Launching in Japan with Colorectal and Bladder indications; finalizing reimbursement/pricing with Ministry of Health, targeting announcement at J.P. Morgan conference.
• Clinical Trial Acceleration: Accelerating enrollment of multiple Phase I, II, and III MRD trials to support pharma partnerships and data generation.

Risks and Headwinds to Outlook:

• COGS Pressure: New products (Fetal Focus, Signatera Genome) currently carry higher COGS, potentially diluting margins in the near term (18–24 months) despite plans to reduce costs.
• Reimbursement Timing: While 9–10 Molde-X submissions are in flight, exact timing and phasing of approvals are uncertain.
• ASP Volatility: Management notes diagnostics ASPs do not always improve linearly; guidance assumes steady ASPs despite potential upside.
• True-Ups: Guidance excludes "true-ups" (revenue adjustments); future quarters may still see some true-up contribution but not modeled in guidance for simplicity.
• Clinical Trial Delays: Large Phase 3 trials (Sagittarius, AFT70) have multi-year readout horizons and are not required to hit the 2029 target, representing a long-term risk/uncertainty.

Management Tone on the Future:

• Confidence: High confidence in hitting the $6B by 2029 target, describing it as "highly achievable" through execution rather than "miracles."
• Strategic Continuity: Solomon emphasizes no "big radical change" in strategy; commitment to the "formula" of practice-changing data, trusted results, and customer service.
• Investment Stance: "Keep foot on the gas" for 2027 OPEX; willing to "weather short-term pressure on COGS" to capture long-term ASP and volume upside.
• Long-Term View: Optimistic on 70%+ gross margins long-term and $2,000+ ASPs for Signatera, viewing current guidance as conservative.

Miscellaneous:

• Market Size Context: HCC affects ~40,000 new U.S. patients/year (3/4 early stage); Bladder Cancer, Head & Neck, and Lymphoma add tens of thousands of additional U.S. patients annually.
• Data Asset Value: Natera possesses unique data on >500,000 patients with linked genomic/clinical data, creating a moat for pharma partnerships.
• Employee Base: Company scale expanded from ~45 people (2011) to 6,500 employees under Solomon's tenure.
• Legal/Compliance: Forward-looking statements made as of November 5, 2026; no obligation to update statements if called after this date.